Similar documents
Key words: Norfloxacin (NFLX), Infectious enteritis, Double-blind method

Fig. 1 Chemical structure Lomefloxacin(LFLX,NY-198) Pipemidic acid(ppa)


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Fig. 1 Chemical structure of DL-8280


coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMOTHERAPY

Fig. 1 Chemical structure of KW-1070

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL.42 S-1

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus


CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

Table1MIC of BAY o 9867 against standard strains

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Fig. 1 Chemical structure of norfioxacin (AM-715)

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection


Fig.1 Chemical structure of BAY o 9867

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


CHEMOTHERAPY



Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo




VOL. 43 NO. 4


2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

日本化学療法学会雑誌第53巻第S-3号

CHEMOTHERAPY FEB Table 1 Background of volunteers

988 CHEMOTHERAPY NOV. 1971

Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det



CHEMOTHERAPY

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

VOL. 34 S-2 CHEMOTH8RAPY 913

CHEMOTHERAPY JUNE 1986


Key words: Antibodies to Leptospira, Tokyo, Uveitis

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

M CHEMOTHERAPY DEC ciprofloxacin(cpfx), ofloxacin(oflx) Staphylococcus aureus, Streptococcus pneumoniae Bacteroides fragi. Haemophilus influenza

Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination

VOL.39 S-3



CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,


CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎


表紙ＰＤＦ作成用／ＰＤＦ表紙作成用

Table 1 Age distribution 1966, , 5 ( ): Carrier Table 2 Symptoms of 38 patients with the typhoid fever Fig. 1 Annual Incidence of Typhoid Fever

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)


VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof


400 CHEMOTHERAPY JAN Table 1 Cases of drop outs

10.fiÁŁÊ−é›æ†Q‘t

Transcription:

Key words: pazufloxacin, infectious enteritis, antibacterial activity, fecal concentration, fecal microflora

: Table 1-1 Criteria for bacteriological efficacy of pazufloxacin on Shigella spp. and V. cholerae 01 : administration of PZFX : administration of another antimicrobial agent : culture positive culture negative (): culture after discharge from hospital E: discharge from hospital ex: example PZFX, ofloxacin (OFLX), ciprofloxacin

Table 1-2 Criteria for bacteriological efficacy of pazufloxacin on the causative isolates except for Shigella spp. and V. cholerae 01

Table 2 Number of cases analysed Table 3 Age and sex distribution of the cases evaluated for clinical and/or bacteriological efficacy

Table 4-1 List of cases evaluated for clinical and bacteriological efficacy Table 4-2 List of polymicrobial infection Table 5 Clinical efficacy of pazufloxacin

Table 6 Bacteriological efficacy of pazufloxacin Table 7 Side effects Table 8 Abnormal changes in laboratory findings *Abnormal value

Table 9 Clinical usefulness of pazufloxacin Table 10-1 Minimum inhibitory concentrations of pazufloxacin and other quinolones against clinical isolates *Đg/ml (inoculum size; 106 cells/ml)

Table 10-2 Minimum inhibitory concentrations of pazufloxacin and other quinolones against clinical isolates (inoculum size; 106 cells/m1) Table 11 Concentration of pazufloxacin in the feces : not detected NT: not tested

Fig. 1 Effects of PZFX on fecal microflora

1) Muratani T, Inoue M & Mitsuhashi S : In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother 1992; 36: 2293-2303. 2) Fukuoka Y, Ikeda Y, Yamashiro Y, Takahashi M, Toda Y & Narita H : In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother 1993 ; 37: 384-392. 5) Segreti J, Gootz TD, Goodman LJ et al.: High-level quinolone resistance in clinical isolates of Carnpylobacter jejuni. J Infect Dis 1992, 165: 667-670.

Basic and Clinical Studies of Pazufloxacin on Infectious Enteritis Research Group of T-3761 on Infectious Enteritis (Manager; Shoichiro IRIMAJIRI) Hiroko SAGARA & Kouji YOSHIKAWA Department of Infectious Diseases, Yokohama Municipal Citizen's Hospital Isao TOMIZAWA & Yoshihiko TAKIZAWA Department of Infectious Diseases, Minamigaoka Branch, Sapporo City General Hospital Yoshiro NITTA, Takafumi TSUNODA & Hiroyuki FUKUDA Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital Tsuyoshi YAMAGUCHI, Gohta MASUDA, Masayoshi NEGISHI & Atsushi AJISAWA Department of Infectious Diseases, Tokyo Metropolitan Komagome General Hospital Misako MURATA & Kenji OHNISHI Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital Shoichiro IRIMAJIRI & Mitsuo OBANA Department of Internal Medicine, Kawasaki Municipal Hospital Fumio MATSUMOTO, Takero IMAI, Iwao SAKURAI & Takayuki TAKAHASHI Department of Internal Medicine, Kanagawa Prefectural Midwives Nurses Training Hospital Masamiki MORI, Yoshiki MIZUNO & Kohji KATOH Department of Communicable Diseases, Nagoya City Higashi General Hospital Shiro HOSODA, Tadao BAMBA & Masaya SASAKI Second Department of Internal Medicine, Shiga Univresity of Medical Science Kunio YOSHIKAWA & Shuichi HIROTANI Department of Internal Medicine, Nagahama Red Cross Hospital Takeshi OGASAWARA, Hitoshi SAKUMOTO & Yasunobu KOMAI Department of Internal Medicine, Otsu Municipal Hospital

Shinobu NAKAJO & Hirozumi OBATA Department of Internal Medicine, Osaka Prefectural Saiseikai Suita Hospital Hideo OOKUBO & Young Ki KIM Department of Communicable Diseases, Kyoto City Hospital Yoshihiro SAKAUE, Hideki YOSHIDA & Tetsushi GOTO Infectious Disease Center, Osaka City General Hospital Tadakazu AISAKA & Motoko MIKAMI Department of Internal Medicine, Hiroshima City Funairi Hospital Kazunori KAGAWA Department of Internal Medicine, Kure National Hospital Yatsuka IMAGAWA & Masafumi FUKUYAMA College of Enviromental Health, Azabu University Yoshio MATSUBARA Department of Internal Medicine, Kiyose Jogu Hospital Makoto SAITO Showa University A clinical study was carried out on pazufloxacin (PZFX) in 137 patients including shigellosis, Salmonella enteritis, enteropathogenic Esherichia coli enteritis and cholera, and carriers of these pathogens. Antibacterial activity of PZFX against clinical isolates, fecal concentration of PZFX and effects of PZFX on fecal microflora were also investigated. The overall clinical efficacy rate was 97.2%. The bacteriological efficacy rates were 98.2% against Shigella spp., 81.8% against Salmonella spp., 50% against Vibrio cholerae 01, and 100% against E. coli, V. parahaemolyticus, Aer - onomas spp., Plesionomas shigelloides and V. cholerae non-01, respectively. Side effect (epigastralgia) was observed in 1 of 130 cases (0.8%). The rate of abnormal laboratory findings was 11.2% (11/98). These were mainly elevation of GOT and/or GPT and increased eosinophils. The clinical usefulness rate was 95.2%. The MICH values of PZFX against Shigella spp., Salmonella spp. and E. coli were 0.025, 0.025 and 0.025,ug/ml, respectively. The results of fecal drug concentration and the effects on fecal microflora in one patient were compatible with those obtained in healthy volunteers.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック